Vivera Pharmaceuticals' Chief Medical Officer Dr. Stephen J. McColgan Appointed Clinical Instructor At University of California, Riverside, School of Medicine

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Newport Beach, California--(Newsfile Corp. - August 14, 2019) - Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management is pleased to announce that its Chief Medical Officer, Dr. McColgan, has been appointed as Clinical Instructor at the University of California, Riverside (UCR), School of Medicine. The UCR School of Medicine is known for successfully developing new methods and frontiers in medical teaching. Dr. McColgan joined the faculty effective August 1, 2019.

"It is both an honor and a privilege to receive this appointment," said Dr. McColgan. "Coming from a private practice background rather than a purely academic one, it's an exciting opportunity for me to be able to offer a different perspective to impact new medical students."

Dr. McColgan was one of the first surgeons to perform laparoscopic cholecystectomy, laparoscopic nissen fundoplication, and laparoscopic gastric bypass in the Southern California area. He was Chairman of the Department of Surgery for Bellflower Medical Center for more than 10 years and was a founding member of Endodynamix, Inc., a manufacturer of surgical instruments.

According to rankings published by the Center for World University Rankings, a consultancy based in the United Arab Emirates, UCR is among the top 1% of universities in the world. In the recently released 2019-2020 list, UCR came in at 204 out of 18,000 total universities worldwide, moving up in rankings from last year. Institutions are evaluated on the quality of teaching, alumni employment, quality of faculty, research output, high-quality publications, influence and citations.

"UCR is recruiting the top, best and brightest in the world," said Greg Cervantes, Director of Government Affairs for Vivera. "I believe adding Dr. McColgan to their faculty is a tremendous benefit to the field of medicine and research. I congratulate Dr. McColgan and view him as one of the nation's top physicians."

"Dr. McColgan's appointment speaks volumes to his accomplishments and reputation," said Paul Edalat, Chairman and Founder of Vivera. "At Vivera, we've always viewed him as a distinguished member amongst his peers so it's great to see that UCR recognizes that as well."

Dr. McColgan was born in Boston, Massachusetts. He is a graduate of Boston University and the Boston University School of Medicine. He completed his general surgery training at the University of California, Irvine, where he served as Chief Resident. In addition, he earned an MBA from the University of California, Irvine.

Figure 1: Dr. Stephen J. McColgan

Cannot view this image? Visit:

To view an enhanced version of this graphic, please visit:

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit

Investor Relations Inquiries:
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.

Press Inquiries:
Karin Elz, for Vivera Pharmaceuticals, Inc.

To view the source version of this press release, please visit

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).